Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 in Chronic Myelomonocytic Leukemia
Key Insights
The FDA has granted Fast Track designation to STX-0712, Solu Therapeutics (search)' investigational therapy for relapsed or refractory chronic myelomonocytic leukemia (search) (CMML (search)).
STX-0712 is a novel CyTAC (search) (Cytotoxicity Targeting Chimera) that targets CCR2 (search)-positive malignant monocytes and bone marrow blasts driving disease progression.
The company is conducting a Phase 1 study in CMML (search) and acute myeloid leukemia (search) patients, with initial clinical data expected at a hematology conference later this year.
Solu Therapeutics (search) announced that the U.S. Food and Drug Administration has granted Fast Track designation to STX-0712, the company's investigational therapy for treating relapsed or refractory chronic myelomonocytic leukemia (search) (CMML (search)). The designation recognizes the significant unmet medical need in CMML, an aggressive blood cancer with limited treatment options for patients whose disease has relapsed or become resistant to available therapies.
Novel Targeting Mechanism
STX-0712 represents a new class of therapeutic called CyTAC (search) (Cytotoxicity Targeting Chimera), which targets the G-protein coupled receptor CCR2 (search). This receptor is expressed at high levels on malignant monocytes and bone marrow blasts, which are key drivers of disease in CMML (search) and other hematologic cancers. By eliminating CCR2-positive cells, STX-0712 aims to provide a more targeted treatment approach with minimal effects on non-malignant cells.
"By directly depleting CCR2 (search)-positive malignant monocytes and bone marrow blasts that drive disease in CMML (search), STX-0712 has the potential to offer a highly specific and targeted approach," said Philip Vickers, President and CEO of Solu Therapeutics (search).
Clinical Development Progress
The company is currently conducting a Phase 1, open-label, multicenter study evaluating STX-0712 as monotherapy in patients with relapsed or refractory CMML (search) and acute myeloid leukemia (search) (AML (search)). Initial clinical data from this ongoing study is planned for submission to a hematology conference later this year.
Beyond CMML (search), Solu Therapeutics (search) is exploring STX-0712's potential in other hematologic malignancies (search), including AML (search), where CCR2 (search)-positive cells also play a role in disease progression.
Regulatory Advantages
Fast Track designation is designed to facilitate development and expedite review of drugs treating serious conditions with unmet medical needs. The designation enables more frequent interactions with the FDA throughout the development and review process, potentially accelerating the path to market for promising therapies.
Vickers emphasized the company's commitment to advancing the therapy quickly: "We look forward to continuing to work closely with the FDA as we advance through clinical development and work to bring this potential therapy to patients as quickly as possible."
Technology Platform
STX-0712 is developed using Solu Therapeutics (search)' proprietary CyTAC (search) platform, which is exclusively licensed from GSK. This platform combines the target-binding capability of small molecules with the therapeutic power of biologics, enabling the development of innovative medicines that eliminate disease-driving cells in cancer and other therapeutic areas.